Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-hepatectomy TACE with camrelizumab + sorafenib versus TACE + sorafenib for recurrence in liver cancer
ChiCTR2100053957Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and sorafenib in liver cancer and hepatocellular carcinoma (HCC) (2 arms), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Recurrence rate at 6 months after surgery. Started Dec 2021; status: recruiting.
02
Drugs
camrelizumabsorafenib
03
Conditions
liver cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100053957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053957.